logo
Share SHARE
FONT-SIZE Plus   Neg

Valeant Pharma To Take Earnings Hit On Mylan's Zovirax Generic Launch

Canadian drug maker Valeant Pharmaceuticals International, Inc. (VRX: Quote,VRX.TO: Quote) announced Thursday that it will be launching an 'authorized generic' of genital herpes drug Zovirax ointment later in the day. The move comes a day after Mylan, Inc. (MYL: Quote) received final approval to launch Acyclovir Ointment USP, 5%, a generic version of Zovirax ointment.

"Yesterday, Mylan announced they had received approval of a generic Zovirax® ointment. While the timing of a generic approval was always uncertain, this was not unforeseen and we were prepared for its eventuality. In response to the new generic approval, we will be launching an authorized generic of Zovirax® ointment today," Valeant Chairman and CEO Michael Pearson said in a statement.

Meanwhile, the Mississauga, Ontario-based specialty pharmaceutical company said the Acyclovir launch is expected to negatively impact its fiscal 2013 cash earnings by about $0.30 to $0.40 per share. Valeant added it did not include the 'isolated event' in its original budget expectations.

However, the company noted it will likely mitigate the impact of the generic introduction with the positive effect of several product acquisitions, the repricing of term-loan debt and other events that have occurred since it provided financial guidance in January.

Valeant had revealed in January that it expected to post cash earnings in a range of $5.45 to $5.75 per share for fiscal 2013.

"We continue to expect once again to deliver outstanding performance in 2013 and we will provide an update to our 2013 guidance on our first quarter financial results conference call in May," Pearson added.

Zovirax Ointment is indicated as a treatment for initial genital herpes and in limited non-life-threatening mucocutaneous herpes simplex virus infections in immunocompromised patients. Mylan's Acyclovir is the first generic version of Valeant's Zovirax Ointment.

According to IMS Health, Acyclovir Ointment USP, 5% had U.S. sales of about $230 million for the 12 months ended December 31, 2012. Mylan will start shipping Acyclovir Ointment immediately.

In Thursday's regular trading session, VRX is currently trading at $71.64, down $0.63 or 0.32% on a volume of 1.17 million shares. In the past 52-week period, the stock has been trading in a broad range of $42.47 to $76.56.

VRX.TO is currently trading on the TSX at $72.37, down $0.54 or 0.74% on a volume of 0.17 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Fortune has once again named Google Inc. (GOOG, GOOGL) as the best company to work for, with Twitter Inc. (TWTR) also joining the annual list for the first time. This is for the sixth time and for the fourth consecutive time that Google has ranked No.1 in the Fortune's annual list of "100 Best Companies... Dunkin' Donuts has agreed to remove a whitening agent called titanium dioxide, commonly a source of nanomaterials, from all powdered sugar used in its donuts. The move follows pressure from advocacy group As You Sow, which put a shareholder proposal asking Dunkin' to reduce the risks of using nanomaterials in its food products. Warren Buffett's Berkshire Hathaway is reportedly planning its first ever European bond sale of 3 billion euros to take advantage of low interest rates in the region, traversing a path taken by a range of home companies in search of cheap funding options. The move comes as the European Central Bank's bond-buying stimulus program of 60 billion euros a month is imminent.
comments powered by Disqus
Follow RTT